Our Mission

To eliminate breast cancer care inequalities by transforming the speed, cost and accuracy of recurrence risk prediction

Our Story

As medical research scientists, ‘hope’ as a strategy for cancer care was not an option. We wanted to turn the hope that clinicians and their patients would get an accurate predictive test in good time, and at an affordable price, into a reality.

For patients, the risk of cancer recurrence is one of their greatest fears. For clinicians, the risk of recurrence is a key indicator to guide post-operative care, provide a personalised medicinal approach, and forms a critical part of the treatment decision-making pathway that guides whether chemotherapy is required or not.

So, we started a digital revolution in cancer risk and understanding.

By uniquely combining infrared multi-spectral imaging (spectrometry) with artificial intelligence we made a breakthrough.

We developed a way of eliminating the subjectivity inherent in traditional biomarker analysis… In a radically faster way … At a dramatically lower cost.

Thereby creating an opportunity to accelerate informed treatment decision-making and advance cancer patient outcomes.

What the experts say

Time Saving
"Digistain cuts down wait times for results massively when compared to our current provider who is sending samples to the US for analysis. The turnaround time with Digistain is much quicker, it is more accurate and cheaper. “The backlogs caused by the pandemic and industrial actions mean that fast-paced technology like this can really be the difference between life and death. “I have worked for the National Health Service for 25 years and it is innovation like this that will open up a new digital pathway and frontier for the NHS - and help future-proof it. It can only be a matter of time before Digistain is adopted across the whole of the NHS."

Sharaz KhanNHS Head of Pathology at the Northampton General Hospital

Patient stratification
"Digistain has shown statistically significant prognostic ability for HR-positive HER2-negative primary operable breast cancer by accurately stratifying patients into high and low risk. With currently over-burdened healthcare systems and the need to improve global cancer care inequalities, the ability to provide low-cost, rapid, and widely accessible prognostic testing suggests that Digistain may have the potential for significant clinical utility".

Dr Charles CoombesDirector, Cancer Research UK Imperial Centre

Prognostic accuracy
“Typical prognostic factors such as the NPI (the gold standard used across the world) have a hazard ratio of around 2. A hazard ratio >4 is excellent. Digistain® appears to be a much better classifier of risk than other biomarkers I’ve seen used in clinics today”

Professor Andrew Green Faculty of Medicine & Health Sciences. Nottingham University

Accessible cost
"It gives the same information about the need for chemotherapy at almost one-fourth the current costs. The new invention can help patients who have been detected with early stage breast cancer and only a few women benefit from chemotherapy at this stage."

Manish Singhal MD, DM(AIIMS)Senior Consultant Medical Oncology at Apollo Hospitals

Proteomic approach
“When clinicopathological factors are augmented with objective assessment of grading, risk evaluation consistency outperforms genomic risk prediction.”

Professor William Dooley, MD FACSProfessor of Surgical Oncology, Johns Hopkins University